Novo Nordisk shares jumped as much as 4% in Denmark. Hims will stop offering compounded semaglutide after the first quarter, ...
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we ...
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won't be selling it for much longer. Hims & Hers Health Inc.'s stock plunged last week when the Food ...
Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...
Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said ...
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Novo Nordisk shares jumped 5.02% during early deals. On Monday, American telehealth firm Hims & Hers said in its earnings ...
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...
Plus, more takeaways from the famed investor’s 2024 letter to shareholders, including Berkshire’s growing Japanese investments and record tax bill.